New York State Psychiatric Institute, New York, USA.
J Clin Psychiatry. 2010 Sep;71(9):1187-95; quiz 1252-3. doi: 10.4088/JCP.09m05328gry.
Prior research has consistently documented a strong association between generalized anxiety disorder (GAD) and substance use disorder (SUD). Comorbidity of GAD and SUD (GAD-SUD) represents clinical challenges, as the patients' symptoms are often more severe and are frequently prolonged, making their management more complex when compared with individuals with GAD only. The purpose of this study was to examine whether individuals with GAD-SUD differ meaningfully from individuals with GAD and no SUD comorbidity (GAD-NSUD) in terms of demographic characteristics, risk factors, psychiatric comorbidity, and clinical correlates.
Data were derived from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (N = 43,093). Diagnoses were made using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version.
We found that the lifetime prevalence rate of GAD-SUD is about 2.04%, while that of GAD-NSUD is 2.10%. Individuals with GAD-SUD showed higher psychiatric comorbidity rates than those with GAD-NSUD. Treatment-seeking rates for GAD are equally low in individuals with GAD-SUD and GAD-NSUD. Both groups were as likely to receive pharmacologic treatment for anxiety.
The findings of our study indicate that individuals with GAD-SUD constitute half of the lifetime prevalence of GAD and that GAD-SUD is associated with high overall vulnerability for additional psychopathology, particularly in the externalizing spectrum; higher disability; and higher use of alcohol and drugs to relieve anxiety symptoms.
先前的研究一致记录了广泛性焦虑障碍(GAD)和物质使用障碍(SUD)之间的强烈关联。GAD 和 SUD 的共病(GAD-SUD)代表了临床挑战,因为患者的症状通常更严重且经常持续时间更长,与仅患有 GAD 的个体相比,其管理更为复杂。本研究的目的是检查在人口统计学特征、风险因素、精神共病和临床相关性方面,患有 GAD-SUD 的个体与患有 GAD 且无 SUD 共病(GAD-NSUD)的个体是否有明显差异。
数据来自 2001-2002 年全国酒精和相关条件流行病学调查(N=43093)。使用酒精使用障碍和相关障碍访谈表-DSM-IV 版本进行诊断。
我们发现 GAD-SUD 的终生患病率约为 2.04%,而 GAD-NSUD 的终生患病率为 2.10%。与 GAD-NSUD 相比,患有 GAD-SUD 的个体表现出更高的精神共病率。寻求 GAD 治疗的比率在 GAD-SUD 和 GAD-NSUD 个体中同样较低。两组接受焦虑症药物治疗的可能性相同。
我们研究的结果表明,患有 GAD-SUD 的个体构成了 GAD 终生患病率的一半,并且 GAD-SUD 与更高的总体易感性相关,特别是在外显谱中;更高的残疾;以及更多地使用酒精和药物来缓解焦虑症状。